Martin Shkreli

• Consider SMH as a hedge against concentrated semiconductor exposure; it was described as roughly 80% correlated with the S&P 500, though no hedge ratio was specified.
• The clearest bullish ideas were AMD and Amphenol (APH); research each before adding, as no price targets or timeframes were provided.
• The strongest short ideas were IonQ (IONQ) and Lam Research (LRCX); treat these as higher-risk trades and verify the thesis before acting.

• Monitor Alphabet (GOOGL), Microsoft (MSFT), Apple (AAPL), and Amazon (AMZN) earnings for capital-spending signals that could support or weaken the SanDisk (SNDK), Micron (MU), and memory-and-storage trade; avoid oversized positions without a specific thesis.
• Intel (INTC) was a tentative value-oriented long after significant weakness, but the discussion offered no clear catalyst or price target, so treat it as a higher-uncertainty idea.
• The bearish ideas in Wolfspeed (WOLF) and Rigetti (RGTI) lacked price targets and detailed fundamental support; given volatility and limited evidence, do not treat them as established short recommendations.
• After a drawdown, reduce position sizes, avoid trying to recover losses quickly, and define what would invalidate each trade before entering.

• Avoid or consider a speculative short in RXRX: the speaker sees its roughly $2 billion valuation as unsupported by its pipeline and flags about $375 million in annual cash burn and dilution risk; no price target was provided.
• Treat TWST cautiously rather than shorting outright: the business is growing, but its roughly $10 billion valuation assumes sustained high growth despite low margins and projected losses through 2028.
• Do not act on the ASML “blowout earnings” claim—it was unverified hearsay, and trading on material nonpublic information carries legal risk.
• Avoid averaging down in NKTR without a clear, independently researched investment thesis; the speaker offered no evidence-based turnaround case.

• Consider Seagate (STX) only as a cautious short-term trade: the sell-off may be an overreaction to an unconfirmed Toshiba bidding-war report, but sharp volatility makes headline risk high.
• The clearest bearish view is Twist Bioscience (TWST), which the host said could have 50% more downside; treat that as an opinion, not a price target, and account for the risk of a continued rally.
• Avoid acting on unverified claims about ASML or the reported buyout of Option Care Health (OPCH) until company disclosures confirm the details.

Kulicke & Soffa (KLIC) is the clearest research opportunity: fiscal 2026 revenue guidance is about $1.2 billion, with potential AI and advanced-packaging demand, but verify newer-product adoption and cyclical risks before buying; the discussion cited a $70 Needham target versus an unsubstantiated $140–$150 upside scenario.
Treat PTC’s takeover approach as a watchlist catalyst only until a bidder and offer terms are confirmed.
Avoid trading on unverified headlines about Intel (INTC), TSMC (TSM), or Tesla (TSLA), and on Vaxcyte (PCVX)’s sharp post-trial-data move without reviewing the clinical results and upcoming milestones.

• Consider buying the dip in Seagate (STX): the speaker expects a potential rebound to $850–$880, but Toshiba’s capacity expansion and Seagate’s failed rally add near-term risk.
• SanDisk (SNDK) also drew bullish interest, but similar storage-market concerns and the speaker’s acknowledgment of excessive position size argue against concentrated exposure.
• The clearest short-term bearish call was Applied Optoelectronics (AAOI), which the speaker viewed as an intraday short after a 6% rise; no longer-term thesis or target was provided.

• Liquidia (LQDA) is the clearest high-upside, high-risk idea: consider it only if you can tolerate further volatility, since the $100 outcome depends on winning an appeal with no timeline provided.
• Micron (MU) has a positive near-term outlook after strong earnings and guidance; the speaker expects it to keep grinding higher, though he held no position.
• Avoid treating a Bitcoin (BTC) short—especially at 40× leverage—as an actionable trade: fees add up quickly, and the speaker acknowledged Bitcoin could move against the position.
• The comments on Moderna (MRNA) were bearish, but lacked a stated thesis, target, or timeframe, so they do not support a well-defined short.

• MongoDB (MDB) is the clearest short-term bullish setup in the discussion, with a trader’s target of $400 over roughly a week; a $350/$400 call spread may limit risk versus buying calls outright, while selling puts carries substantial downside.
• Moderna (MRNA) could see a short-term rebound after its roughly 7% downgrade-driven decline, but this is a speculative momentum and short-covering trade—not a strong long-term buy thesis.
• Avoid treating Liquidia (LQDA) as a dip-buy after United Therapeutics (UTHR) won the patent case; the ruling creates meaningful commercial uncertainty, and proposed entry levels below $30 were high-risk trader opinions.
• Treat Micron (MU) earnings as a volatility event, not a directional signal: the discussion offered no reliable forecast or price target.

• MongoDB (MDB) was the clearest short-term long: the host favored buying around $325 and expected $340 by the end of the day; treat that as a high-risk, same-day trade, not a long-term target.
• Micron (MU) earnings were flagged for the following day as a potential volatility catalyst; monitor results and guidance before taking a position.
• The host remains bearish on Kodiak Sciences (KOD) and estimates it may be $50–$60 or more overvalued, but crowded short interest and squeeze risk make shorting especially risky.

• KOD is a clinical catalyst, not yet a confirmed commercial opportunity: Daybreak showed comparable trial results to aflibercept, with many patients reaching six-month dosing, but real-world durability and payer access remain unproven.
• Watch for KSI-101’s forthcoming data and the KSI-501 DME superiority study; neither has results here to support a trade yet.
• Before investing in KOD, look for evidence in previously treated patients and clarity on insurance step therapy, which may limit adoption.

• Consider the long SanDisk (SNDK) / short Intel (INTC) pair as a relative-value trade, but monitor upcoming Micron (MU) and Meta (META) commentary for evidence of sustained memory demand and enterprise AI adoption.
• Kodiak Sciences (KOD) is a highly speculative short ahead of Monday’s trial data; avoid treating it as a low-risk trade, since a positive surprise could cause substantial losses.
• Avoid broad AI-related shorts based solely on high valuations: the speaker expects IPO-driven enthusiasm could persist through 2028, and warns that timing can be costly.

Treat IonQ (IONQ) and Rigetti (RGTI) as highly speculative: commercial uses remain uncertain, and sharp rallies can make short positions dangerous. Avoid leveraged Bitcoin (BTC) futures unless you fully understand margin and liquidation rules; the discussion offers no reliable short-term directional edge. Watch Viking Therapeutics (VKTX) for financing and clinical updates before taking a position, given concerns about cash needs and an uncertain drug-program outlook. Be cautious with semiconductor shorts such as Micron (MU) and SanDisk (SNDK): possible supply and demand headwinds were raised, but no specific targets or confirmed catalysts were provided.

• Nidec (NIDEC) is the clearest favorable new-name idea: research its motor and disk-drive exposure, with the discussion citing roughly 11× EBITDA; no price target was given.
• Lam Research (LRCX) was suggested as a possible long against SanDisk (SNDK), but the rationale was limited and the pair trade remains unconfirmed; investigate further before acting.
• AI-related NVMe flash demand may support SanDisk, but competition and sharp volatility make it a high-risk, uncertain trade rather than a clear buy.
• Avoid treating Jaguar Health (JAGX) as an investment: the discussion described a volatile, hard-to-borrow short-squeeze setup with potential for abrupt reversals.

Consider buying Ultragenyx Pharmaceutical (RARE) as an undervalued growth play with potential acquisition upside targeting $30 to $40. Buy Bloom Energy (BE) to benefit from rising AI power infrastructure demand, and accumulate Micron Technology (MU) for long-term semiconductor upside toward $1,050 to $1,500. Treat recent price dips in Meta Platforms (META) as high-conviction buying opportunities supported by robust underlying fundamentals. Short IonQ (IONQ) around $39 due to unproven commercial viability in quantum computing, along with Pfizer (PFE) amid severe drug pipeline headwinds. Lock in profits on recent price surges in Advanced Micro Devices (AMD), while strictly avoiding toxic microcaps like QCLS that face severe dilution risks.

Consider a long position in Ultragenyx Pharmaceutical (RARE) following its steep 47% sell-off, targeting a rebound toward $40–$50 per share based on its depressed valuation of roughly 2x sales. Position for upside in memory semiconductor producers like fundamentally strong Micron Technology (MU) and SanDisk, which are primed to benefit from potential U.S. tariffs on competitor SK Hynix. Consider short positions on Moderna (MRNA) as the company faces sustained downside pressure and an uncertain commercial pipeline. Watch for tactical short-selling setups in Robinhood Markets (HOOD) to capitalize on potential pullbacks following its rapid, crypto-fueled rally. Finally, stay invested in resilient enterprise software leaders like Snowflake (SNOW) as fears over AI disruption subside, while actively avoiding speculative quantum computing stocks that lack near-term commercial viability.

Rotate exposure from NVIDIA (NVDA) into Taiwan Semiconductor Manufacturing Company (TSM) to capitalize on the tech sector's structural shift toward custom ASICs. Within mega-cap tech, prioritize the stability and strong execution of Microsoft (MSFT) and Apple (AAPL) over margin-pressured peers like Amazon (AMZN) and Meta Platforms (META). Capitalize on recent clinical selloffs by buying undervalued core assets in Ultragenyx Pharmaceutical (RARE), while treating Spruce Biosciences (SPRB) as a patient, long-term opportunity toward a $500 price target. Short or avoid Capricor Therapeutics (CAPR) and Amylyx Pharmaceuticals (AMLX) ahead of expected product-launch headwinds and questionable trial data. Protect overall capital by applying disciplined Kelly Criterion position sizing and dollar-neutral sector hedging instead of taking oversized, unhedged bets.

Consider a long position in Spruce Biosciences (SPRB) for upside on anticipated FDA approval, while risk-tolerant investors can target an oversold rebound in Alumis Inc. (ALMS).

Actively position for downside or hold short exposure on Moderna (MRNA) and Kinsale Capital Group (KNSL) due to deteriorating growth trajectories and unfavorable valuations.

Avoid or immediately exit long positions in Inventiva (IVA) ahead of upcoming binary PPAR clinical trial readouts that carry severe downside risk toward zero.

Steer clear of speculative traps, including the heavily dilutive GoPro (GPRO) reverse merger, the overvalued AI neo-cloud provider Nebius Group (NBIS), and highly manipulated micro-cap meme coins.

Protect capital during market uncertainty by allocating funds toward cash and fixed-income bonds yielding roughly 5% to preserve purchasing power against inflation.

For NVIDIA (NVDA), look to fade sharp post-earnings spikes while holding for long-term growth, as projected 70% revenue expansion in fiscal 2028 outweighs near-term gross margin pressure.

Sell or short Salesforce (CRM) around the $231 post-earnings level, where the recent double-digit rally appears driven by short-covering rather than strong underlying growth.

Maintain a high-conviction short position on Moderna (MRNA) to profit from ongoing cash burn and declining core franchise revenues.

Deploy conservatively sized short trades on Capricor Therapeutics (CAPR) due to high skepticism surrounding lead asset FDA approval, while strictly managing risk against potential short squeezes.

Look for tactical intraday short setups on Meta Platforms (META) during market pullbacks as the stock absorbs headwinds from a potential $16 billion regulatory settlement.

Investors can capitalize on downside momentum by shorting Moderna (MRNA) toward a target of $100, while also targeting high-conviction short positions in Capricor Therapeutics (CAPR) down to $6.00 and SELLAS Life Sciences (SLS) due to high clinical trial failure risks.

For bullish healthcare plays, Spruce Biosciences (SPRB) offers strong upside potential following recent positive news catalysts, and Biohaven (BHVN) represents a high-conviction long-term hold driven by proven management execution.

In the semiconductor space, consider a long position in Broadcom (AVGO) to benefit from the growing enterprise shift toward custom artificial intelligence chip design.

Active traders should look to short or avoid speculative rallies in the Quantum Computing Sector, as recent price surges lack fundamental revenue backing.

Finally, steer clear of microcap Solana Meme Tokens, which carry severe risks of capital loss due to illiquid markets and high price manipulation.